Cigna Corp (CI) Director Sells $45,812.96 in Stock

Share on StockTwits

Cigna Corp (NYSE:CI) Director William D. Zollars sold 272 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $168.43, for a total value of $45,812.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NYSE:CI traded down $3.11 during trading hours on Friday, reaching $166.45. The stock had a trading volume of 3,753,106 shares, compared to its average volume of 2,930,273. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.42 and a quick ratio of 0.42. Cigna Corp has a 12-month low of $162.42 and a 12-month high of $226.60. The company has a market capitalization of $64.80 billion, a P/E ratio of 11.71, a P/E/G ratio of 0.81 and a beta of 0.73.

Cigna (NYSE:CI) last released its earnings results on Friday, February 1st. The health services provider reported $2.46 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.53 by ($0.07). Cigna had a return on equity of 16.64% and a net margin of 5.42%. The firm had revenue of $13.75 billion during the quarter, compared to analysts’ expectations of $11.38 billion. During the same period in the prior year, the business earned $1.94 earnings per share. The business’s quarterly revenue was up 29.3% compared to the same quarter last year. As a group, analysts anticipate that Cigna Corp will post 16.41 earnings per share for the current year.

The company also recently announced a special dividend, which will be paid on Wednesday, April 10th. Shareholders of record on Monday, March 11th will be given a $0.04 dividend. The ex-dividend date of this dividend is Friday, March 8th. Cigna’s dividend payout ratio is currently 0.28%.

A number of brokerages recently commented on CI. Leerink Swann increased their price target on Cigna from $250.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, November 19th. Raymond James raised Cigna from a “market perform” rating to an “outperform” rating and set a $187.17 price target for the company in a research report on Thursday, January 3rd. ValuEngine raised Cigna from a “sell” rating to a “hold” rating in a research report on Thursday, January 3rd. Edward Jones began coverage on Cigna in a research report on Monday, December 24th. They set a “buy” rating and a $181.30 price target for the company. Finally, Zacks Investment Research raised Cigna from a “hold” rating to a “buy” rating and set a $208.00 price target for the company in a research report on Friday, January 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $231.28.

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its position in Cigna by 56.2% in the fourth quarter. Bank of New York Mellon Corp now owns 3,304,407 shares of the health services provider’s stock worth $627,573,000 after buying an additional 1,189,307 shares during the last quarter. Brave Asset Management Inc. purchased a new stake in Cigna in the fourth quarter worth $243,000. South State Corp increased its position in Cigna by 143.4% in the fourth quarter. South State Corp now owns 5,235 shares of the health services provider’s stock worth $994,000 after buying an additional 3,084 shares during the last quarter. First Financial Corp IN increased its position in Cigna by 10.1% in the fourth quarter. First Financial Corp IN now owns 786 shares of the health services provider’s stock worth $150,000 after buying an additional 72 shares during the last quarter. Finally, Hexavest Inc. grew its position in shares of Cigna by 96.1% in the fourth quarter. Hexavest Inc. now owns 506,320 shares of the health services provider’s stock valued at $96,160,000 after purchasing an additional 248,082 shares in the last quarter. 93.44% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/4224523/cigna-corp-ci-director-sells-45812-96-in-stock.html.

Cigna Company Profile

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.

Featured Story: Preferred Stock

Insider Buying and Selling by Quarter for Cigna (NYSE:CI)

Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

WEC Energy Group Inc  Position Cut by Dean Investment Associates LLC
WEC Energy Group Inc Position Cut by Dean Investment Associates LLC
Cambria Investment Management L.P. Acquires 3,550 Shares of SPDR S TR/CITI INTL GOVT INFL
Cambria Investment Management L.P. Acquires 3,550 Shares of SPDR S TR/CITI INTL GOVT INFL
Cedar Brook Financial Partners LLC Buys 140 Shares of ProShares Ultra S&P500
Cedar Brook Financial Partners LLC Buys 140 Shares of ProShares Ultra S&P500
Cooper Companies Inc  Shares Bought by Commerce Bank
Cooper Companies Inc Shares Bought by Commerce Bank
Cambridge Investment Research Advisors Inc. Acquires 9,232 Shares of VANGUARD SCOTTS/VANGUARD SHORT-TERM
Cambridge Investment Research Advisors Inc. Acquires 9,232 Shares of VANGUARD SCOTTS/VANGUARD SHORT-TERM
SALT   Trading 18.2% Lower  Over Last Week
SALT Trading 18.2% Lower Over Last Week


© 2006-2019 Ticker Report